Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
This research study is investigating a drug called inebilizumab for children and adolescents between 2 and 17 years old who have a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). These young people must also have specific antibodies in their blood called AQP4-IgG. The main goals of the study are to understand how the medicine moves through the body (pharmacokinetics), what effects it has on the body (pharmacodynamics), and how safe it is. Participants will receive the medicine intravenously over 28 weeks, and their health will be closely monitored throughout the study, which could last up to 80 weeks.
A colpo d'occhio
Di cosa tratta questo studio?
This study is focused on a rare condition called Neuromyelitis Optica Spectrum Disorder, or NMOSD. It's a condition where the body's immune system mistakenly attacks its own healthy cells, particularly in the brain and spinal cord, leading to a range of symptoms. This particular study is for children and teenagers aged between 2 and 17 years old who have been diagnosed with NMOSD and have a specific type of antibody in their blood.
The research aims to find out more about a new treatment called inebilizumab. It's important to understand how new medicines work in young people because their bodies can react differently compared to adults. The study will look at how the medicine is absorbed and used by the body, what effects it has, and how safe it is for this age group.
By carefully studying inebilizumab, researchers hope to gather important information that could help in the development of new and effective treatments for children and teenagers with NMOSD in the future. This kind of research is vital for improving the lives of those affected by rare conditions.
Punti chiave
- This study is for children and teenagers with a specific type of NMOSD.
- It's testing a new medicine called inebilizumab given intravenously.
- The main goals are to check the medicine's safety and how it works in the body.
- Participation involves regular clinic visits over a period of up to 80 weeks.
- Your health will be closely monitored throughout the study.
- Puoi ritirarti dallo studio in qualsiasi momento.
Chi può essere idoneo?
To be considered for this study, participants must be between 2 and 17 years old, weigh at least 15 kg (about 2 stone 5 pounds), and have a clear diagnosis of NMOSD. They also need to have tested positive for specific antibodies (called AQP4-IgG) in their blood and have experienced at least one NMOSD relapse in the past year, or two or more relapses in the past two years.
There are also some reasons why someone might not be able to join. For example, if they have other significant health problems affecting their liver, kidneys, or blood, or if they are currently taking part in another drug study. Also, if they have recently received certain other treatments for NMOSD or similar conditions, they might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you between 2 and 17 years old?
- Do you weigh at least 15 kg?
- Have you been diagnosed with Neuromyelitis Optica Spectrum Disorder?
- Have you had a positive blood test for AQP4-IgG antibodies?
- Have you experienced an NMOSD relapse in the last year, or two or more in the last two years?
- Are you currently free from other major health issues or recent specific treatments that might prevent your participation?
Cosa comporta la partecipazione?
If you join this study, you would receive the study medicine, inebilizumab, directly into your vein (intravenously) over a period of 28 weeks. The study involves several visits to the clinic. First, there's a screening period of up to 4 weeks to check if you're suitable. Then, during the 28-week treatment period, you'll have about 9 visits. After that, there's a follow-up period of about 52 weeks, with approximately 4 visits to monitor your health. The total time you would be involved in the study could be up to 80 weeks (about a year and a half). Your health will be regularly checked throughout this time to ensure your safety and monitor the effects of the treatment.
Rischi e benefici potenziali
Locations (19)
- UCSD Altman Clinical and Translational Research Institute BuildingCodice postale verificatoLa Jolla, Stati Uniti· Reclutamento
- Loma Linda University Children's Hospital - PINCodice postale verificatoLoma Linda, United States· Reclutamento
- Massachusetts General HospitalCodice postale verificatoBoston, Stati Uniti· Reclutamento
- University of Texas Southwestern Medical CenterCodice postale verificatoDallas, Stati Uniti· Reclutamento
- Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. GarrahanCodice postale verificatoParque Patricios, Argentina· Reclutamento
- Hospital Santa Izabel-Rua Floriano Peixoto 300Codice postale verificatoSalvador, Brazil· Reclutamento
- Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)Non verificatoPorto Alegre/RS, Brazil· Reclutamento
- CPQuali Pesquisa Clínica Sao PauloCodice postale verificatoSão Paulo, Brazil· Reclutamento
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São PauloCodice postale verificatoSão Paulo, Brazil· Reclutamento
- Hospital For Sick ChildrenCodice postale verificatoToronto, Canada· Reclutamento
- Centre Hospitalier Universitaire de BicêtreCodice postale verificatoLe Kremlin-Bicêtre, France· Reclutamento
- Erasmus MC Sophia Children's Hospital-Wytemaweg 80Codice postale verificatoRotterdam, Paesi Bassi· Reclutamento
Domande comuni
What is NMOSD?
NMOSD is a rare condition where your body's immune system mistakenly attacks healthy cells, mainly in the brain and spinal cord.
What is inebilizumab?
Inebilizumab is the medicine being investigated in this study. It's a potential new treatment for NMOSD that aims to help manage the condition.
Come verrà somministrato il medicinale?
The medicine will be given directly into a vein (intravenously), meaning through a drip.
Per quanto tempo sarò nello studio?
If you join, the study participation could last for up to 80 weeks, which includes treatment and follow-up periods.
Posso lasciare lo studio in qualsiasi momento?
Yes, you have the right to withdraw from the study at any point, and it won't affect your ongoing medical care.
Come saperne di più
Amgen Call Center
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.